Treatment for Endogenous Cushing's Syndrome
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01838551|
Recruitment Status : Active, not recruiting
First Posted : April 24, 2013
Last Update Posted : February 16, 2018
|Condition or disease||Intervention/treatment||Phase|
|Endogenous Cushing's Syndrome||Drug: COR-003||Phase 3|
This will be a single period, open-label, dose titration study to assess efficacy, safety, tolerability, and PK of COR-003 in subjects with CS. The trial design will identify both the minimally effective and maximally tolerated doses in this CS population. Following an initial screening period, this study will be conducted in 2 treatment phases as follows:
- Dose titration phase: approximately 2 to 16 weeks to achieve an effective and tolerable maximum dose (the therapeutic dose)
- Maintenance phase: 6 months of treatment at the therapeutic dose without a prior dose increase following the establishment of the appropriate dose identified in the titration phase;
- Extended evaluation phase: 6 months of continued treatment after the maintenance phase (6 - 12 months); dose adjustments will be allowed as required for treatment
Efficacy will be assessed by measuring UFC concentrations at specified times as described in the clinical protocol.
Blood samples for the PK determination will be collected at the times indicated in the clinical protocol.
An independent Data Safety Monitoring Board (DSMB) will review the safety of the drug throughout the study. The constituents of the DSMB membership and a adjudication committee is specifically described in the clinical protocol.
Subjects completing the 6-month maintenance phase of the study will remain in the study for an additional 6 months for extended evaluations.
COR-003 will be provided under a compassionate use protocol for subjects who wish to continue treatment with COR-003.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||90 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open Label Study to Assess the Safety and Efficacy of COR-003 (Levoketoconazole) in the Treatment of Endogenous Cushing's Syndrome|
|Study Start Date :||August 2014|
|Estimated Primary Completion Date :||April 2018|
|Estimated Study Completion Date :||October 2018|
Male or female, ≥18 year of age, or of a minimal age as required by the local regulations with confirmed diagnosis of CS as defined according to the criteria in the guidelines for diagnosis of CS (Nieman 2008).
- Reduction in urinary free cortisol in patients with endogenous Cushing's Syndrome. [ Time Frame: 6 months of maintenance phase therapy without a prior dose increase during that phase ]The response to COR-003 is defined as mean UFC concentration ≤ULN following 6 months of maintenance phase therapy without a prior dose increase during that phase.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01838551
Show 42 Study Locations
|Study Director:||Fredric J Cohen, MD||Cortendo AB|